A new trading day began on Friday, with Seres Therapeutics Inc (NASDAQ: MCRB) stock price down -0.86% from the previous day of trading, before settling in for the closing price of $0.84. MCRB’s price has ranged from $0.54 to $1.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 477.44% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 86.52%. With a float of $124.81 million, this company’s outstanding shares have now reached $170.20 million.
In an organization with 233 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -258259.37%.
Seres Therapeutics Inc (MCRB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Seres Therapeutics Inc is 26.90%, while institutional ownership is 23.42%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.41% during the next five years compared to 18.22% growth over the previous five years of trading.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Here are Seres Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2369.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Let’s dig in a bit further. During the last 5-days, its volume was 0.72 million. That was inferior than the volume of 1.76 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 68.12%. Additionally, its Average True Range was 0.06.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 43.64%, which indicates a significant decrease from 63.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.36% in the past 14 days, which was lower than the 94.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8467, while its 200-day Moving Average is $0.8965. However, in the short run, Seres Therapeutics Inc’s stock first resistance to watch stands at $0.8517. Second resistance stands at $0.8706. The third major resistance level sits at $0.8815. If the price goes on to break the first support level at $0.8219, it is likely to go to the next support level at $0.8110. The third support level lies at $0.7921 if the price breaches the second support level.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
With a market capitalization of 142.18 million, the company has a total of 170,738K Shares Outstanding. Currently, annual sales are 126,330 K while annual income is -113,720 K. The company’s previous quarter sales were 0 K while its latest quarter income was 88,780 K.
